Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Obinutuzumab plus len promising in untreated FL

Loretta Nastoupil • 7 Dec 2019
ASH 2019
B-Cell Lymphoma Follicular Lymphoma Lymphoma Non-Hodgkin Lymphoma Antibodies Lenalidomide Obinutuzumab Rituximab

Loretta Nastoupil, MD, University of Texas MD Anderson Center, Houston, TX, discusses the results of the phase II trial (NCT01582776) of obinutuzumab, a monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity (ADCC), with lenalidomide in previously untreated, high tumor burden follicular lymphoma (FL). This drug combination was associated with high complete response and manageable toxicities. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Loretta Nastoupil

1:10
NHL: What's hot at ASH 2023?
Loretta Nastoupil • 8 Dec 2023
2:20
Tazemetostat + lenalidomide & rituximab vs. lenalidomide & rituximab in patients with R/R FL
Loretta Nastoupil • 8 Dec 2023
1:48
TRANSCEND FL: liso-cel as 2L therapy in patients with high-risk R/R follicular lymphoma
Loretta Nastoupil • 8 Dec 2023
1:51
Optimizing immunotherapy for 3L or later R/R follicular lymphoma: liso-cel versus mosunetuzumab
Loretta Nastoupil • 8 Dec 2023

Related Videos

1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
2:28
Checkpoint inhibitors vs brentuximab vedotin as salvage therapy prior to alloSCT for HL
Jacopo Mariotti • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals